Riverview Capital Advisers, LLC Coherus Bio Sciences, Inc. Transaction History
Riverview Capital Advisers, LLC
- $324 Million
- Q3 2025
A detailed history of Riverview Capital Advisers, LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Riverview Capital Advisers, LLC holds 12,946 shares of CHRS stock, worth $15,405. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,946Holding current value
$15,405% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
126Shares Held
54.7MCall Options Held
291KPut Options Held
120K-
Black Rock Inc. New York, NY11.8MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$12.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$6.07 Million0.38% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$3.61 Million0.2% of portfolio
-
Geode Capital Management, LLC Boston, MA2.74MShares$3.26 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $92.5M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...